Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:AIMD

Ainos Q1 2026 Earnings Report

Ainos logo
$1.74 +0.03 (+1.75%)
Closing price 05/14/2026 03:58 PM Eastern
Extended Trading
$1.72 -0.02 (-0.92%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Ainos EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
After Market Closes
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Ainos' Q1 2026 Press ReleasePress Release
(8-K)
Ainos' Q1 2026 Quarterly reportQuarterly report
(10-Q)

Ainos Earnings Headlines

AIMD Using AI Technology to Advance Semi Manufacturing
May 14 at 2:59 PM  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/technology/articles/aimd-using-ai-technology-advance-100700030.html
Ainos, Inc.: Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets
May 14 at 9:59 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68490007-ainos-inc-ainos-reports-first-quarter-2026-financial-results-and-highlights-smell-ai-execution-across-semiconductors-and-healthcare-infrastructure-200.htm
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.tc pixel
May 15 at 1:00 AM  |  American Alternative (Ad)
Ainos, Inc.: Ainos Updates Standard Industrial Classification Code to Reflect Smell AI Business Focus
May 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68456475-ainos-inc-ainos-updates-standard-industrial-classification-code-to-reflect-smell-ai-business-focus-200.htm
Ainos, Inc.: VASRO: Ainos Expands Smell AI from Industrials into Healthcare Infrastructure, Reinforcing AI Infrastructure Positioning and Multi-Vertical Scalability
April 17, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68228895-ainos-inc-vasro-ainos-expands-smell-ai-from-industrials-into-healthcare-infrastructure-reinforcing-ai-infrastructure-positioning-and-multi-vertic-200.htm
Ainos stock jumps 5% on healthcare AI expansion plans
April 17, 2026  |  in.investing.comhttps://in.investing.com/news/company-news/ainos-stock-jumps-5-on-healthcare-ai-expansion-plans-93CH-5343294
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD) (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials.

Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.

View Ainos Profile
Earnings Tools